FDA 483 - Custom Compounding Center - June 04, 2019

An FDA inspection of Custom Compounding Center in Little Rock, AR, revealed a significant issue regarding the production of hazardous drugs. The firm failed to implement adequate cleaning procedures, specifically not using an oxidizing agent, to prevent cross-contamination of drug products containing testosterone, estrogen, and morphine. This indicates a serious concern for product quality and patient safety.